(Q24655266)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jeffrey Bajramovic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

10

Geoff Hale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Kathryn Chapman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Lee Coney

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Maggie Dempster

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Laura Andrews

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Paul Baldrick

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Lorrene Buckley

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Abby Jacobs

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Colin Green

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ian Ragan

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Vicky Robinson

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

30 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

published in

Monoclonal Antibodies

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

505-516

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

16 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Alternative strategies for toxicity testing of species-specific biopharmaceuticals

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Translational strategies for development of monoclonal antibodies from discovery to the clinic.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Monoclonal antibodies as innovative therapeutics

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Preclinical and clinical safety of monoclonal antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Loss of Siglec expression on T lymphocytes during human evolution

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Principles of the therapeutic use of monoclonal antibodies in oncology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Antibody targeted drugs as cancer therapeutics

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Placental transport of immunoglobulin G.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations

30 May 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.5.9676

Preclinical safety testing of monoclonal antibodies: the significance of species relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.5.9676

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.5.9676

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.5.9676

Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.5.9676

Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759500

Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required

28 November 2018

1 reference

12 December 2020

Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4

1 reference

12 December 2020

Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody

1 reference

12 December 2020

Monoclonal antibody successes in the clinic

1 reference

12 December 2020

Monoclonal antibody therapy of cancer

1 reference

12 December 2020

Anti-infective monoclonal antibodies: perils and promise of development

1 reference

12 December 2020

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab

1 reference

12 December 2020

Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections

1 reference

12 December 2020

Preclinical safety evaluation of monoclonal antibodies

1 reference

12 December 2020

International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice

1 reference

12 December 2020

Identifiers

DOI

10.4161/MABS.1.5.9676

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065651%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

PubMed publication ID

20065651

1 reference